• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Viral Molecular Diagnostics: Market Developments, Growth Areas and Opportunities 2014 - Product Image

Viral Molecular Diagnostics: Market Developments, Growth Areas and Opportunities 2014

  • Published: March 2014
  • Region: Global
  • 147 Pages
  • BioPharm Reports (VennBio Ltd.)

In general, viral diagnostic tests can be grouped into three areas, namely, direct detection, indirect examination following virus isolation, and serology. Direct methods generally test for virus particles, virus antigen or viral nucleic acids, while indirect approaches involve culture and isolation. Historically, serology has been the mainstay of activities in the virology laboratory, where antibody titre methods are important. However, the last decade has seen increasing use of direct tests, notably with the evolution of molecular methods, which is the subject of the current study. This report presents the findings from a new market study of viral molecular diagnostics, and gives commercial insights to suppliers in this field.

Market studies carried out by Biopharm Reports are designed to assist laboratory suppliers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user needs, our studies assist suppliers to sell into these markets, and support innovation, READ MORE >

Executive Summary

1. Introduction
1.1. Introduction
1.2. Market questions

2. Study Participants
2.1. Introduction
2.2. Global regions
2.3. Country
2.4. Job title
2.5. Experience
2.6. Organisation type
2.7. Field
2.8. Purpose
2.9. Role
2.10. Main activity
2.11. Discussion

3. Associated Therapeutic Areas
3.1. Introduction
3.2. Market questions
3.3. Associated therapeutic area
3.4. Discussion

4. Main Viruses
4.1. Introduction
4.2. Market questions
4.3. Current viruses
4.4. Future viruses
4.5. Discussion

5. General Virus Tests
5.1. Introduction
5.2. Market questions
5.3. Current tests
5.4. Other current tests
5.5. Future tests
5.6. Other future tests
5.7. Discussion

6. Study Samples
6.1 Introduction
6.2. Market questions
6.3. Sample types
6.4. Other samples
6.5. Discussion

7. Viral Molecular Techniques
7.1. Introduction
7.2. Market questions
7.3. Current techniques
7.4. Other current techniques
7.5. Future techniques
7.6. Other future techniques
7.7. Discussion

8. Main Viruses Tested using Molecular Diagnostics
8.1. Introduction
8.2. Market questions
8.3. Current main viruses tested
8.4. Future main viruses tested
8.5. Discussion

9. Multiple Virus Testing
9.1. Introduction
9.2. Market questions
9.3. Current multiple virus testing
9.4. Future multiple virus testing
9.5. Discussion

10. Multiplex Methods
10.1. Introduction
10.2. Market questions
10.3. Current multiplex methods
10.4. Future multiplex methods
10.5. Discussion

11. Viral Molecular Diagnostic Growth Trends
11.1. Introduction
11.2. Market questions
11.3. Current growth
11.4. Future growth
11.5. Discussion

12. Viral Molecular Diagnostic Applications
12.1. Introduction
12.2. Market questions
12.3. Current main applications
12.4. Other current applications
12.5. Future main applications
12.6. Other future applications
12.7. Discussion

13. Suppliers of Viral Molecular Diagnostics
13.1. Introduction
13.2. Market questions
13.3. Current suppliers
13.4. Other current suppliers
13.5. Future suppliers
13.6. Other Future suppliers
13.7. Discussion

14. Advantages and Disadvantages of Viral Molecular Diagnostics
14.1. Introduction
14.2. Market questions
14.3. Advantages
14.4. Disadvantages
14.5. Discussion

15. Future Requirements of Viral Molecular Diagnostics
15.1. Introduction
15.2. Market questions
15.3. Future requirements
15.4. Discussion

16. Techniques being Replaced by Viral Molecular Tests
16.1. Introduction
16.2. Market questions
16.3. Techniques being replaced
16.4. Discussion

17. Automation of Viral Molecular Diagnostics
17.1. Introduction
17.2. Market questions
17.3. Automation
17.4. Preferred Suppliers
17.5. Discussion

18. Most Tested Viruses
18.1. Introduction
18.2. Market questions
18.3. Most tested viruses
18.4. Costs
18.5. Budget
18.6. Discussion

19. Discussion

Figures

Figure 2.1. Global regions of participants in VMD 2014
Figure 2.2. Countries of participants in VMD 2014
Figure 2.3. Job titles of participants in VMD 2014
Figure 2.4. Viral diagnostics experience of participants in VMD 2014
Figure 2.5. Organisations of participants in VMD 2014
Figure 2.6. Fields of participants in VMD 2014
Figure 2.7. Purpose of viral diagnostics activities of participants in VMD 2014
Figure 2.8. Role of participants in VMD 2014
Figure 2.9. Main activity of participants in VMD 2014
Figure 3.2. Associated therapeutic areas participants work in, relating to viral molecular diagnostics
Figure 4.2. Main viruses currently treated or worked with, indicated by participants in VMD 2014
Figure 4.3. Main viruses anticipated to be treated or worked with in three years from now, indicated by participants in VMD 2014
Figure 5.2. Main general tests currently used, indicated by participants in VMD 2014
Figure 5.4. Main general viral tests anticipated to be used in three years from now, indicated by participants in VMD 2014
Figure 6.2. Main sample types tested in viral diagnostics, indicated by participants in VMD 2014
Figure 7.2. Main viral molecular diagnostic techniques currently used, indicated by participants in VMD 2014
Figure 7.4. Main viral molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in VMD
Figure 8.2. Main viruses currently tested using molecular diagnostics, indicated by participants in VMD 2014
Figure 8.4. Main viruses anticipated to be tested using molecular diagnostics in three years from now, indicated by participants in VMD 2014
Figure 9.2. The number of different viruses currently simultaneously tested, indicated by participants in VMD 2014
Figure 9.3. The number of different viruses anticipated to be simultaneously tested in three years from now, indicated by participants in VMD 2014
Figure 10.2. The percentage of current viral molecular tests that are based on multiplex methods, indicated by participants in VMD 2014
Figure 10.3. The percentage of viral molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in VMD 2014
Figure 11.2. The change (% increase or % decrease) in the use of viral molecular diagnostics tests over the last three years, indicated by participants in VMD 2014
Figure 11.3. The change (% increase or % decrease) in the use of viral molecular diagnostics tests anticipated over the next three years, indicated by participants in VMD 2014
Figure 12.2. Current main applications of viral molecular diagnostics, indicated by participants in VMD 2014
Figure 12.4. Main applications of viral molecular diagnostics anticipated in three years from now, indicated by participants in VMD 2014
Figure 13.2. Current main suppliers of viral molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in VMD 2014
Figure 13.4. Main suppliers of viral molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in VMD 2014
Figure 14.2. The main advantages of viral molecular diagnostics compared to other (non-molecular) methods used in viral diagnostics, indicated by participants in VMD 2014
Figure 14.4. The main disadvantages of viral molecular diagnostics compared to other (non-molecular) methods used in viral diagnostics, indicated by participants in VMD 2014
Figure 15.2. Main areas where end-users would like to see future improvements in viral molecular diagnostics, indicated by participants in VMD 2014
Figure 16.2. Techniques used in viral diagnostics that have been, or are being, replaced by viral molecular diagnostics methods, indicated by participants in VMD 2014
Figure 17.2. Percentage of end-users viral molecular diagnostics that are automated, indicated by participants in VMD 2014
Figure 17.3 Preferred suppliers of automated molecular diagnostic systems, indicated by participants in VMD 2014
Figure 18.2. Most tested viruses, in terms of the numbers of viral molecular diagnostic tests carried out, indicated by participants in VMD 2014
Figure 18.3. Cost per test (including associated replicates and controls) of thee most tested virus using the associated molecular diagnostic, indicated by participants in VMD 2014
Figure 18.4. Percentage of budgets associated with the single viral molecular diagnostic tests indicated previously referred to, indicated by participants in VMD 2014
Figure 18.5. Preferred suppliers of the molecular diagnostic tests for the most tested viruses, indicated by participants in VMD 2014

Tables

Table 2.1. Global regions of participants in VMD 2014
Table 2.2. Countries of participants in VMD 2014
Table 2.3. Job titles of participants in VMD 2014
Table 2.4. Viral diagnostics experience of participants in VMD 2014
Table 2.5. Organisations of participants in VMD 2014
Table 2.6. Fields of participants in VMD 2014
Table 2.7. Purpose of viral diagnostics activities of participants in VMD 2014
Table 2.8. Role of participants in VMD 2014
Table 2.9. Main activity of participants in VMD 2014
Table 3.2. Associated therapeutic areas participants work in, relating to viral molecular diagnostics
Table 4.2. Main viruses currently treated or worked with, indicated by participants in VMD 2014
Table 4.3. Main viruses anticipated to be treated or worked with in three years from now, indicated by participants in VMD 2014
Table 4.5. Anticipated changes in the treatment or investigation of specific viruses over the next three years, indicated by participants in VMD 2014
Table 5.2. Main types of viral tests currently used, indicated by participants in VMD 2014
Table 5.3. Other general viral tests currently used, indicated by participants in VMD 2014
Table 5.4. Main general viral tests anticipated to be used in three years from now, indicated by participants in VMD 2014
Table 5.5 Anticipated changes in the use of general viral tests in three years from now, indicated by participants in VMD 2014
Table 6.2. Main sample types tested in viral diagnostics, indicated by participants in VMD 2014
Table 6.3 Other samples types tested in viral diagnostics, indicated by participants in VMD 2014
Table 7.2. Main viral molecular diagnostic techniques currently used, indicated by participants in VMD 2014
Table 7.4. Main viral molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in VMD
Table 7.6. Anticipated changes in the use of viral molecular diagnostic techniques over the next three years, indicated by participants in VMD
Table 8.2. Main viruses currently tested using molecular diagnostics, indicated by participants in VMD 2014
Table 8.4. Main viruses anticipated to be tested using molecular diagnostics in three years from now, indicated by participants in VMD 2014
Table 8.5. Changes in the viruses anticipated to be tested using molecular diagnostics in three years from now, indicated by participants in VMD 2014
Table 9.2. The number of different viruses currently simultaneously tested, indicated by participants in VMD 2014
Table 9.3. The number of different viruses anticipated to be simultaneously tested in three years from now, indicated by participants in VMD 2014
Table 10.2. The percentage of current viral molecular tests that are based on multiplex methods, indicated by participants in VMD 2014
Table 10.3. The percentage of viral molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in VMD 2014
Table 11.2. Changes in the use of viral molecular diagnostics tests over the last three years, indicated by participants in VMD 2014
Table 11.3. Anticipated changes in the use of viral molecular diagnostics tests anticipated over the next three years, indicated by participants in VMD 2014
Table 12.2. Current main applications of viral molecular diagnostics, indicated by participants in VMD 2014
Table 12.4. Main applications of viral molecular diagnostics anticipated in three years from now, indicated by participants in VMD 2014
Table 13.2. Current main suppliers of viral molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in VMD 2014
Table 13.4. Anticipated suppliers of viral molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in VMD 2014
Figure 13.6. Anticipated changes in suppliers of viral molecular diagnostics (e.g. diagnostics kits, reagents) in three years from now, indicated by participants in VMD 2014
Table 14.2. The main advantages of viral molecular diagnostics compared to other (non-molecular) methods used in viral diagnostics, indicated by participants in VMD 2014
Table 14.4. The main disadvantages of viral molecular diagnostics compared to other (non-molecular) methods used in viral diagnostics, indicated by participants in VMD 2014
Table 15.2. Main areas where end-users would like to see future improvements in viral molecular diagnostics, indicated by participants in VMD 2014
Table 16.2. Techniques used in viral diagnostics that have been, or are being, replaced by viral molecular diagnostics methods, indicated by participants in VMD 2014
Table 17.2. Percentage of end-users viral molecular diagnostic tests that are automated, indicated by participants in VMD 2014
Figure 17.3 Preferred suppliers of automated molecular diagnostic systems, indicated by participants in VMD 2014
Table 18.2. Most tested viruses, in terms of the numbers of viral molecular diagnostic tests carried out, indicated by participants in VMD 2014
Table 18.3. Cost per test (including associated replicates and controls) of the most tested virus using the associated molecular diagnostic, indicated by participants in VMD 2014
Table 18.4. Percentage of budgets associated with the single viral molecular diagnostic tests indicated previously referred to, indicated by participants in VMD 2014
Table 18.5. Preferred suppliers of the molecular diagnostic tests for the most tested viruses, indicated by participants in VMD 2014

Market findings from this study are based on 'real world' laboratory data, provided by research scientists and clinicians in the viral molecular diagnostics field.

This study investigated 45 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on the current and evolving use of viral molecular diagnostics and assist companies selling into these markets to respond to laboratory users’ current needs and their future plans.

Biopharm Reports specialises in carrying out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos